Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03433274 · ClinicalTrials.gov registry record · NA
Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation
A NA study of Cardiovascular Diseases and Mitral Regurgitation, sponsored by Abbott Medical Devices.
- Active
- Registry status
- NA
- Development phase
- 103
- Enrollment target
- 20
- Study locations
NCT03433274 is a NA study of Cardiovascular Diseases and Mitral Regurgitation that is active but no longer recruiting, run by Abbott Medical Devices. The registered enrollment target is 103 participants, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT03433274, a NA study of Cardiovascular Diseases and Mitral Regurgitation, is active but no longer recruiting, sponsored by Abbott Medical Devices.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 103 participants
- Enrollment target
- 20
- Study locations
Study Summary
Prospective, controlled, multicenter clinical investigation with four trial cohorts: Randomized, Non-repairable, Severe Mitral Annular Calcification (MAC) and Severe Mitral Annular Calcification Continued Access Plan (MAC CAP). Subjects in the Randomized cohort were randomized in a 1:1 ratio to the trial device or to the MitraClip system. Subjects in the Non-repairable, Severe MAC, and Severe MAC CAP cohorts were receive the trial device. The objective of the Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation (SUMMIT) was to evaluate the safety and effectiveness of the Tendyne Transcatheter Mitral Valve System for the treatment of patients with symptomatic, moderate-to-severe or severe mitral regurgitation or for patients with symptomatic mitral valve disease due to severe mitral annular calcification. This randomized controlled trial would provide the opportunity to evaluate the safety and clinical benefits of the Tendyne Transcatheter Mitral Valve System compared to the MitraClip System in patients with symptomatic, moderate-to-severe or severe mitral regurgitation, within approved MitraClip indications. In addition, the safety and effectiveness of the Tendyne Transcatheter Mitral Valve System would be evaluated in patients with severe mitral annular calcification who are at prohibitive risk for mitral valve surgery. Patients who were not suitable for mitral valve surgery for reasons other than severe mitral annular calcification and were also not suitable for transcatheter repair with MitraClip, would be enrolled in the Non-repairable cohort. Subjects would be seen at screening, pre- and post-procedure, discharge, 30 days, 3 months, 6 months, and annually through 5 years.
Conditions Studied
Interventions
- DEVICE Tendyne Mitral Valve System
- DEVICE MitraClip System
Study Locations (20)
California
- Fresno Heart Hospital - Fresno
- University of Southern California University Hospital - Los Angeles
- Cedars-Sinai Medical Center - Los Angeles
- Sutter Medical Center, Sacramento - Sacramento
- University of California - Davis Medical Center - Sacramento
- San Diego Cardiac Center - San Diego
- University of California at San Francisco - San Francisco
- Stanford Health Care - Stanford
- Los Robles Regional Medical Center - Thousand Oaks
Florida
- Manatee Memorial Hospital - Bradenton
- BayCare Healthcare System - Morton Plant Hospital - Clearwater
- Delray Medical Center - Delray Beach
- HCA Florida North Florida Hospital - Gainesville
- University of Florida - Gainesville
Alabama
- Baptist Medical Center Princeton - Birmingham
- UAB University Hospital - Birmingham
Arizona
- Banner-University Medical Center - Phoenix
- Scottsdale Healthcare Shea - Scottsdale
Arkansas
- Baptist Health Medical Center - Little Rock
Colorado
- University of Colorado Hospital - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2018-06-15 |
| Est. Completion | 2028-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03433274
The ClinicalTrials.gov registry entry for NCT03433274 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower). The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 2 interventions - of which Tendyne Mitral Valve System is the first listed.
NCT03433274 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT03433274 about?
NCT03433274 is a clinical study titled "Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation". Prospective, controlled, multicenter clinical investigation with four trial cohorts: Randomized, Non-repairable, Severe Mitral Annular Calcification (MAC) and Severe Mitral Annular Calcification Continued Access Plan (MAC CAP). Subjects in the Randomized cohort were randomized in a 1:1 ratio to the ...
What is the current status of trial NCT03433274?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 103 participants. The study started on 2018-06-15. Estimated completion is 2028-06.
What conditions does trial NCT03433274 study?
This clinical trial studies the following conditions: Cardiovascular Diseases, Mitral Regurgitation, Heart Valve Diseases, Mitral Valve Insufficiency, Valve Disease, Heart.
What interventions are being tested in trial NCT03433274?
The interventions under investigation include: Tendyne Mitral Valve System (DEVICE), MitraClip System (DEVICE).
Who is sponsoring clinical trial NCT03433274?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03433274 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Influence of Chardonnay Marc Intake on Gut and Cardiometabolic Health
RECRUITING · NA
-
Identifying Strategies to Reduce Cardiovascular Risk Among Mothers of Young Children
RECRUITING · NA
-
Insomnia Treatment and Cardiometabolic Health in Older Adults With Posttraumatic Stress Disorder
RECRUITING · NA
-
Deep Brain Stimulation Motor Ventral Thalamus (VOP/VIM) for Restoration of Speech and Upper-limb Function in People With Subcortical Stroke
RECRUITING · NA
-
Effects of Whole vs. Nonfat Milk Consumption on Body Composition in Children
RECRUITING · NA
-
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.